(Q43790335)

26 November 2017

title

Multiple sclerosis: modulation of apoptosis susceptibility by glatiramer acetate (English)

1 reference

26 November 2017

Aktas O

1

1 reference

26 November 2017

Ari N

2

1 reference

26 November 2017

Rieks M

3

1 reference

26 November 2017

Hoffmann V

4

1 reference

26 November 2017

Schimrigk S

5

1 reference

26 November 2017

Przuntek H

6

1 reference

26 November 2017

Pöhlau D

7

1 reference

26 November 2017

language of work or name

English

0 references

publication date

1 November 2001

1 reference

Acta Neurologica Scandinavica

26 November 2017

published in

1 reference

26 November 2017

volume

104

1 reference

26 November 2017

issue

5

1 reference

26 November 2017

page(s)

266-270

1 reference

Immunopathogenesis of multiple sclerosis: the role of T cells

26 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2001.00125.X

T-cell apoptosis in autoimmune diseases: termination of inflammation in the nervous system and other sites with specialized immune-defense mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2001.00125.X

Immune (dys)regulation in multiple sclerosis: role of the CD95-CD95 ligand system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2001.00125.X

Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2001.00125.X

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadi

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2001.00125.X

Specific inhibition of the T-cell response to myelin basic protein by the synthetic copolymer Cop 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2001.00125.X

Treatment of multiple sclerosis with copolymer-1 (Copaxone): implicating mechanisms of Th1 to Th2/Th3 immune-deviation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2001.00125.X

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2001.00125.X

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2001.00125.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2001.00125.X

Soluble Fas (Apo-1) levels in cerebrospinal fluid of multiple sclerosis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2001.00125.X

Detection of the soluble form of the Fas molecule in patients with multiple sclerosis and human T-lymphotropic virus type I-associated myelopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2001.00125.X

Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2001.00125.X

Impaired apoptotic deletion of myelin basic protein-reactive T cells in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2001.00125.X

Multiple sclerosis: comparison of copolymer-1- reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2001.00125.X

Increased serum levels of soluble CD95 (APO-1/Fas) in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2001.00125.X

CD95(APO-1/Fas)-mediated apoptosis: live and let die

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2001.00125.X

7 January 2021

T cell deletion in high antigen dose therapy of autoimmune encephalomyelitis

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2001.00125.X

7 January 2021

Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2001.00125.X

7 January 2021

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2001.00125.X

7 January 2021

The autoimmune reactivity to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis is potentially pathogenic: effect of copolymer 1 on MOG-induced disease

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2001.00125.X

7 January 2021

10.1034/J.1600-0404.2001.00125.X

Identifiers

DOI

1 reference

26 November 2017

1 reference